Clinical Trial News and Research

RSS

Bortezomib can improve control of GVHD and immune system recovery

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT).

6 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

New Emergency Stroke System ensures patients’ access to effective treatment

Thanks to Los Angeles County's new Emergency Stroke System, individuals who experience a stroke may now be able to more quickly access some of the latest advances in stroke interventions.

5 Dec 2009

OrthoAccel Technologies announces the availability of new Continuing Education course

OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device to enhance orthodontics, announced the availability of a new Continuing Education course published by PennWell Corporation, a leader in professional education for many industries, including medicine and dentistry.

5 Dec 2009

Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI

Oxygen Biotherapeutics, Inc. today announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

5 Dec 2009

Research participants link high-paying clinical studies to increased risk levels

More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participation.

5 Dec 2009

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

The Multiple Myeloma Research Consortium (MMRC) today announced that it has awarded the Dana-Farber Cancer Institute, and its clinical researchers, Kenneth Anderson, MD, and Paul Richardson, MD, with the 2009 MMRC Center of the Year Award.

5 Dec 2009

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

A coalition of cancer patient advocacy organizations led by the International Myeloma Foundation (IMF) and the MDS Foundation (MDSF), will bring its cancer patient “Statement of Principles” to the 2009 Meeting of the American Society of Hematology (ASH) in New Orleans December 5th through 8th.

4 Dec 2009

FUJIFILM to interface Raytheon BBN Technologies' SDM technology with its Aspire HD FFDM system

Raytheon BBN Technologies, a wholly-owned subsidiary of Raytheon Company, has licensed its patented, award-winning stereo digital mammography (SDM) technology to FUJIFILM Corp.

4 Dec 2009

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.

4 Dec 2009

Data from recent clinical trial for Caldolor Injection to be presented

Cumberland Pharmaceuticals Inc. announced today that data from a recent clinical trial for Caldolor® (ibuprofen) Injection, an intravenous treatment for pain and fever, will be presented at the 44th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting in Las Vegas, Nevada, in December.

4 Dec 2009

Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial

After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.

3 Dec 2009

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

3 Dec 2009

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

iCo Therapeutics Inc. is pleased to announce that an overview of iCo-007, entitled "iCo-007 a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy" will be presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics ("ISOPT"), a major international ocular conference.

3 Dec 2009

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).

3 Dec 2009

Analysis shows fewer victims survive out-of-hospital cardiac arrests

The chance of surviving an out-of-hospital cardiac arrest has not improved since the 1950s, according to a report by the University of Michigan Health System.

3 Dec 2009

AACR offers a compendium of best research practices to aid the FDA in regulating tobacco

When President Barack Obama signed the Family Smoking Prevention and Control Act in June, he ushered in a new era of tobacco policy that empowers the Food and Drug Administration to regulate one of the world's most controversial and deadly consumer products.

3 Dec 2009

Biomoda appeals N.M. congressional delegation to support Lung Cancer Mortality legislation

Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) today urged the New Mexico congressional delegation to support the Lung Cancer Mortality Reduction Act of 2009, which calls for a comprehensive federal program to achieve a 50% reduction in the mortality rate of lung cancer by 2016.

3 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Bristol-Myers Squibb Company today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.

3 Dec 2009

Clinical Trial News and Research

Bortezomib can improve control of GVHD and immune system recovery

New treatment options for leukemia and myeloproliferative disorders introduced

New Emergency Stroke System ensures patients’ access to effective treatment

OrthoAccel Technologies announces the availability of new Continuing Education course

Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI

Research participants link high-paying clinical studies to increased risk levels

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

FUJIFILM to interface Raytheon BBN Technologies' SDM technology with its Aspire HD FFDM system

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Data from recent clinical trial for Caldolor Injection to be presented

Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Analysis shows fewer victims survive out-of-hospital cardiac arrests

AACR offers a compendium of best research practices to aid the FDA in regulating tobacco

Biomoda appeals N.M. congressional delegation to support Lung Cancer Mortality legislation

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer